P151 NONIMMUNITY AGAINST HEPATITIS B VIRUS IN PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE

Posted on January 18, 2018 by Gastroenterology Journal

Currently, there are no data on the prevalence rate of hepatitis B virus (HBV) serologic markers in patients with newly diagnosed inflammatory bowel disease (IBD) in Korea, which is a hepatitis B endemic area.

This entry was posted in News. Bookmark the permalink.